FDA 483 - Octapharma Plasma Inc - January 10, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Octapharma Plasma Inc.'s plasmapheresis center in Cincinnati, OH, revealed a significant issue with adherence to written standard operating procedures. Specifically, employees failed to consistently follow procedures for visually inspecting refractometers for red blood cells during donor screening, potentially impacting the quality and safety of collected blood components. This indicates a breakdown in procedural compliance during critical donor evaluation steps.
- Person
ID · 300e73f6-5f91-483a-b9c1-7078fb24c82f